Referencer

1. Chen Q, Espey MG, Sun AY, et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A. 2007 May 22;104(21):8749-54.

 

2. Du J, Cullen JJ, Buettner GR. Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta. 2012 Dec;1826(2):443-57.

 

3. Klingelhoeffer C, Kämmerer U, Koospal M, et al. Natural resistance to ascorbic acid induced oxidative stress is mainly mediated by catalase activity in human cancer cells and catalase-silencing sensitizes to oxidative stress. BMC Complement Altern Med. 2012 May 2;12:61.

 

4. Doskey CM, Buranasudja V, Wagner BA, et al. Tumor cells have decreased ability to metabolize H₂O₂: Implications for pharmacological ascorbate in cancer therapy. Redox Biol. 2016 Dec;10:274-284.

 

5. Molavian HR, Goldman A, Phipps CJ, et al. Drug-induced reactive oxygen species (ROS) rely on cell membrane properties to exert anticancer effects. Sci Rep. 2016 Jun 9;6:27439.

 

6. Schoenfeld JD, Sibenaller ZA, Mapuskar KA, et al. O₂⋅⁻ and H₂O₂-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 Aug 14;32(2):268.

 

7. Fine EJ, Segal-Isaacson CJ, Feinman R, Sparano J. Carbohydrate restriction in patients with advanced cancer: a protocol to assess safety and feasibility with an accompanying hypothesis. Community Oncol. 2008;5(4):213-220.

 

8. Martuscello RT, Vedam-Mai V, McCarthy DJ, et al. A Supplemented High-Fat Low-Carbohydrate Diet for the Treatment of Glioblastoma. Clin Cancer Res. 2016 May 15;22(10):2482-2495.

 

9. İyikesici MS, Slocum AK, Berkarda FB, Kalamian M, Seyfried TN. Efficacy of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy for Stage IV Triple-Negative Breast Cancer. Cureus. 2017 Jul 7;9(7):e1445.

 

10. Foghsgaard L. Gavnlige bakterier i tarmen kan forlænge kræftspatienters liv. Politiken. 1. Dec. 2017.

 

11. Yun J, Mullarky E, Lu C, et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science. 2015 Dec 11;350(6266):1391-1396.

 

12. Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014 Feb 5;6(222):222ra18.

 

13. Cieslak JA, Cullen JJ. Treatment of Pancreatic Cancer with Pharmacological Ascorbate. Curr Pharm Biotechnol. 2015;16(9):759-770.

 

14. Putchala MC, Ramani P, Sherlin HJ, Premkumar P, Natesan A. Ascorbic acid and its pro-oxidant activity as a therapy for tumours of oral cavity — a systematic review. Arch Oral Biol. 2013 Jun;58(6):563-574.

 

15. Leekha A , Gurjar BS , Tyagi A , Rizvi MA , Verma AK . Vitamin C in synergism with cisplatin induces cell death in cervical cancer cells through altered redox cycling and p53 upregulation. J Cancer Res Clin Oncol. 2016 Dec;142(12):2503-2514.

 

16. Goradel NH , Asghari MH , Moloudizargari M , Negahdari B , Haghi-Aminjan H , Abdollahi M . Melatonin as an angiogenesis inhibitor to combat cancer: Mechanistic evidence. Toxicol Appl Pharmacol. 2017 Nov 15;335:56-63.

 

17. Yeh CM , Su SC , Lin CW , Yang WE , Chien MH , Reiter RJ , Yang SF. Melatonin as a potential inhibitory agent in head and neck cancer. Oncotarget. 2017 Aug;8(52):90545-90556.

 

18. Mark Levine , Sebastian J. Padayatty , and Michael Graham Espey . Vitamin C: A Concentration-Function Approach Yields Pharmacology and Therapeutic Discoveries . Adv Nutr. 2011 Mar; 2(2): 78–88.

 

19. William W. Li, Vincent W. Li, Michelle Hutnik, and Albert S. Chiou. Tumor Angiogenesis as a Target for Dietary Cancer Prevention. Review Article. Journal of Oncology. Volume 2012 (2012), Article ID 879623, 23 pages

 

20. Michael Graham Espey , Ping Chen , Brian Chalmers , Jeanne Drisko , Andrew Y. Sun , Mark Levine and Qi Chen. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med. 2011 Jun 1;50(11):1610-9.

 

21. Holly G. Prigerson , PhD, Yuhua Bao , PhD, Manish A. Shah , MD, M. Elizabeth Paulk , MD, Thomas W. LeBlanc , MD, MA, Bryan J. Schneider , MD, Melissa M. Garrido , PhD, M. Carrington Reid , MD, PhD, David A. Berlin, MD, Kerin B. Adelson , MD, Alfred I. Neugut , MD, PhD, and Paul K. Maciejewski , PhD.: Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncol. 2015 Sep; 1(6): 778–784.

 

22. Parrow NL , Leshin JA , Levine M . Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics. Antioxid Redox Signal. 2013 Dec 10;19(17):2141-56.

 

23. L. John Hoffer , Line Robitaille , Robert Zakarian , David Melnychuk , Petr Kavan , Jason Agulnik , Victor Cohen , David Small , and Wilson H. Miller, Jr. High-Dose Intravenous Vitamin C Combined with Cytotoxic Chemotherapy in Patients with Advanced Cancer: A Phase I-II Clinical Trial. PLoS One. 2015; 10(4): e0120228.

 

24. Pope JL , Tomkovich S , Yang Y , Jobin C: Microbiota as a mediator of cancer progression and theraphy. Transl Res. 2017 Jan;179:139-154.

 

25.Vollbracht C, Schneider B, Leendert V, et al.: Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo 25 (6): 983-90, 2011 Nov-Dec.

 

26. Yeom CH, Jung GC, Song KJ: Changes of terminal cancer patients’ health-related quality of life after high dose vitamin C administration. J Korean Med Sci 22 (1): 7-11, 2007.

 

27. Anitra C. Carr , Margreet C. M. Vissers , and John S. Cook The Effect of Intravenous Vitamin C on Cancer- and Chemotherapy-Related Fatigue and Quality of Life. 2014

 

28. Klimant E, Wright H, Rubin D, Seely D, Markman ; Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach. Curr Oncol. 2018

1. Esteban Escolar, Gervasio A. Lamas, Daniel B. Mark, Robin Boineau, Christine Goertz, Yves Rosenberg, Richard L. Nahin, Pamela Ouyang, Theodore Rozema, Allan Magaziner, Richard Nahas, Eldrin F. Lewis, Lauren Lindblad and Kerry L. Lee;The Effect of an EDTA-based Chelation Regimen on Patients With Diabetes Mellitus and Prior Myocardial Infarction in the Trial to Assess Chelation Therapy (TACT).Circulation: Cardiovascular Quality and Outcomes. 2014;7:15–24

 

2. Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL; Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 2013; 309:1241–1250.

 

3. Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Drisko JA, Lee KL. Design of the Trial to Assess Chelation Therapy (TACT). Am Heart J. 2012;163:7–12.

 

4. Cranton EM, Liu ZX, Smith IM. Urinary trace and toxic elements and minerals in untimed urine specimens. In: Cranton EM, eds. Textbook on EDTA Chelation Therapy, 2nd Ed. Charlottesville, VA: Hampton Roads Publishing Co; 2001:503–539.

 

5. Menke A, Muntner P, Batuman V, Silbergeld EK, Guallar E. Blood lead below 0.48 μmol/L (10 μg/dL) and mortality among US adults. Circulation.2006; 114:1388–1394.

 

6. Nawrot TS, Staessen JA. Low-level environmental exposure to lead unmasked as silent killer. Circulation. 2006;114:1347–1349.

 

7. Navas-Acien A, Selvin E, Sharrett AR, Calderon-Aranda E, Silbergeld E, Guallar E. Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation. 2004;109:3196–3201.

 

8. Tellez-Plaza M, Guallar E, Howard BV, Umans JG, Francesconi KA, Goessler W, Silbergeld EK, Devereux RB, Navas-Acien A.Cadmium exposure and incident cardiovascular disease. Epidemiology.2013;24:421–429.

 

9. Waters RS, Bryden NA, Patterson KY, Veillon C, Anderson RA.EDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zinc. Biol Trace Elem Res. 2001;83:207–221.

1. https://mim.dk/

2.Compston A (2016) The story of multiple sclerosis, Mc Alpine´s Multiple Sclerosis. p.3-68

3.Theodore I Lidsky, Jay S Schneider: Lead neurotoxicity in children: basic mechanisms and clinical correlates. Brain. 2003 Jan;126(Pt 1):5-19.

4.Ahmed Gomaa 1, Howard Hu, David Bellinger, Joel Schwartz, Shirng-Wern Tsaih, Teresa Gonzalez-Cossio, Lourdes Schnaas, Karen Peterson, Antonio Aro, Mauricio Hernandez-Avila: Maternal bone lead as an independent risk factor for fetal neurotoxicity: a prospective study.Pediatrics. 2002 Jul;110(1 Pt 1):110-8.

5.Philippe Grandjean, Philip J Landrigan: Neurobehavioural effects of developmental toxicity. Lancet Neurol. 2014 Mar;13(3):330-8

6.Kanwal Rehman, Fiza Fatima, Iqra Waheed, Muhammad Sajid Hamid Akash: Prevalence of exposure of heavy metals and their impact on health consequencesJ Cell Biochem. 2018 Jan;119(1):157-184.

7.Kaviyarasi Renu, Rituraj Chakraborty, Haritha Myakala, Rajeshwari Koti, Ademola C Famurewa, Harishkumar Madhyastha, Balachandar Vellingiri, Alex George , Abilash Valsala Gopalakrishnan:Molecular mechanism of heavy metals (Lead, Chromium, Arsenic, Mercury, Nickel and Cadmium) - induced hepatotoxicity - A review. Chemosphere. 2021 May:271

8.Rolf Teschke: Aluminum, Arsenic, Beryllium, Cadmium, Chromium, Cobalt, Copper, Iron, Lead, Mercury, Molybdenum, Nickel, Platinum, Thallium, Titanium, Vanadium, and Zinc: Molecular Aspects in Experimental Liver Injury.Int J Mol Sci. 2022 Oct 13;23(20):12213.

9. Xianwei Guo, Wanying Su, Ning Li, Qiuxia Song, Hao Wang, Qiwei Liang, Yaru Li, Scott Lowe, Rachel Bentley, Zhen Zhou, Evelyn J Song, Ce Cheng, Qin Zhou , Chenyu Sun:Association of urinary or blood heavy metals and mortality from all causes,

cardiovascular disease, and cancer in the general population: a systematic review and meta-analysis of cohort studies.Environ Sci Pollut Res Int. 2022 Sep;29(45):67483-67503.

10.Rajiv Chowdhury, Anna Ramond, Linda M O'Keeffe, Sara Shahzad, Setor K Kunutsor, Taulant Muka, John Gregson, Peter Willeit, Samantha Warnakula, Hassan Khan, Susmita Chowdhury, Reeta Gobin, Oscar H Franco, Emanuele Di Angelantonio:Environmental toxic metal contaminants and risk of cardiovascular disease: systematic review and meta-analysis. BMJ. 2018 Aug 29:362

11.Sulagna Dutta, Bapi Gorain, Hira Choudhury, Shubhadeep Roychoudhury, Pallav Sengupta:Environmental and occupational exposure of metals and female reproductive health. Environ Sci Pollut Res Int. 2022 Sep;29(41):62067-62092

  1. Ather Ali 1, Valentine Yanchou Njike, Veronika Northrup, Alyse B Sabina, Anna-Leila Williams, Lauren S Liberti, Adam I Perlman, Harry Adelson, David L Katz: Intravenous micronutrient therapy (Myers' Cocktail) for fibromyalgia: a placebo-controlled pilot study Randomized Controlled Trial J Altern Complement Med. 2009 Mar;15(3):247-57. doi: 10.1089/acm.2008.0410.


  2. Alan R Gaby; Intravenous nutrient therapy: the "Myers' cocktail". Altern Med Rev 2002 Oct;7(5):389-403. PMID:
    12410623


  3. Harri Hemilä: Vitamin C and Infections.Nutrients. 2017 Apr; 9(4): 339.


  4. Stavroula K Osganian 1, Meir J Stampfer, Eric Rimm, Donna Spiegelman, Frank B Hu, JoAnn E Manson, Walter C Willet: Vitamin C and risk of coronary heart disease in women J Am Coll Cardiol. 2003 Jul 16;42(2):246-52


  5. Anitra C. Carr, and Silvia Maggini: Vitamin C and Immune Function.Nutrients. 2017 Nov; 9(11): 1211.


  6. C. Perricone, C. De Carolis, and R. Inhibition of the Complement System by Glutathione: Molecular Mechanisms and Potential Therapeutic Implications. International Journal of Immunopathology and Pharmacolog, Vol 24, no 1., 63-68 (2011)


  7. Boris D Hristov Role of Glutathione Metabolism in Chronic Illness Development and Its Potential Use as a Novel Therapeutic Target. September 2022 Cureus 14(9)


  8. Caroline Rae, Stephen R Williams: Glutathione in the human brain: Review of its roles and measurement by magnetic resonance spectroscopy December 2016 Analytical Biochemistry 529


  9. Elizabeth Harris , Joni Kirk, Renee Rowsell, Luis Vitetta, Avni Sali, Andrew B Scholey, Andrew Pipingas: The effect of multivitamin supplementation on mood and stress in healthy older men. Randomized Controlled Trial Hum Psychopharmacol. 2011 Dec;26(8):560-7


  10. Jerome Sarris, Katherine HM Cox, David A Camfield, Andrew Scholey, Con Stough, Erin Fogg, Marni Kras, David J White, Avni Sali, Andrew Pipingas: Participant experiences from chronic administration of a multivitamin versus placebo on subjective health and wellbeing: a double-blind qualitative analysis of a randomised controlled trial. Nutrition Journal | Issue 1/2012
  1. Renate Viebahn-Hänsler , Olga Sonia León Fernández & Ziad Fahmy (2012): Ozone in Medicine: The LowDose Ozone Concept—Guidelines and Treatment Strategies, Ozone: Science & Engineering: The Journal of the International Ozone Association, 34:6, 408-424


  2. Ajamieh, H.H., S. Menendez, N. Nerino, G. Martinez-Sanchez, L. Re, and O.S. Leon. 2003. “Ischemic and Ozone Oxidative Preconditioning in theProtection Against Hepatic Ischemic-Reperfusion Injury.” Ozone: Sci. Eng. 25: 241–250.


  3. Beck, E.G., G.H. Waßer, and R. Viebahn-Hänsler. 1998. “Ozontherapie in Wissenschaft und Empirie” Z. Komplement. Medizin. 5: 61–75.


  4. Bocci, V., I. Zanardi, and V. Travagli. 2011. “Oxygen/Ozone as a Medical Gas Mixture. A Critical Evaluation“ Med. Gas Res. 1: 6.


  5. Criegée, R. 1975. “Mechanism of Ozone.“ Angew. Chem. Int. Ed. 14: 745–752.


  6. European Communities. 2008. “Directives 2008/50/EC.” Official Journal of the European Union. L152:1–44.


  7. Gough, N.R. 2009. “The Long and Short of Redox Signaling.” Sci. Signal.2(90): 12.


  8. Knoch, H.G., W. Roschke, and W. Klug. 1987. “Die Sauerstoff Ozontherapie in der Proktologie.” Aktuelle Koloproktologie 4: 161–173.


  9. Ozone in Medicine—Guidelines November–December 2012 423


  10. Knoch, H.G., R. Viebahn-Hänsler, and Z. Fahm. 2009. Guidelines. Baden-Baden, Germany: Ärztliche Gesellschaft für Ozonanwendung in Prävention und Therapie.


  11. Léon, O.S., S. Menendéz, N. Merino, R. Castillo, S. Sam, L. Pérez, E. Cruz, and V. Bocci. 1998. “Ozone Oxidative Preconditioning: A Protection Against Cellular Damage by Free Radicals.” Mediators Inflam. 7: 289–294.


  12. Masschelein, W., L. Blaich, E. Thieben, J. Bell, and A. Reading. 1998. “Quality Assurance in Ozone Practice.” Ozone: Sci. Eng. 20(6): 433–498.


  13. Peralta, C., León, O.S., Xaus, C., Prats, N., Sala Planell, E., Puig-Parellada, P., Gelpí, E., and J. Roselló-Catafau. 1999. “Protective Effect of Ozone Treatment on the Injury Associated with Hepatic Ischemia-Reperfusion: Antioxidant-Prooxidant Balance.“ Free Rad. Res. 31: 191–196.


  14. Rattan, I.S. 2008. “Hormesis in Aging.” Ageing Res. Rev. 7: 63–78. 15.Viebahn-Hänsler, R. 2006. “Ozon-Peroxide” als Second-Messenger Moleküle. Zellprotektiver Mechanismus durch Regulation der zellulären Antioxidantien und Radikalfänger.” Ozon-Handbuch. Landsberg/Lech, Germany: Ecomed Publishers.


  15. Werkmeister, H. 1995. “Dekubitalgeschwüre und die Behandlung mit der Ozon-Unterdruckbegasung.” In Ozon-Handbuch, edited by E.G. Beck and R. Viebahn-Hänsler. Landsberg/Lech, Germany: Ecomed Publishers.


  16. World Health Organization (WHO). 2006. Air Quality Guidelines: Global Update 2005. Particulate Matte, Ozone, Nitrogen, Dioxide and Sulfur Dioxide. Copenhagen: WHO Regional Office for Europe